Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01838174 (ClinicalTrials.gov)	May 2013	18/4/2013	A Trial of Neuroprotection With ACTH in Acute Optic Neuritis	A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis	Multiple Sclerosis	Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids)	University of Colorado, Denver	Mallinckrodt;University of Pennsylvania	Terminated	18 Years	55 Years	All	100	Phase 4	United States
2	NCT00418145 (ClinicalTrials.gov)	September 2003	2/1/2007	Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks	Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)	Multiple Sclerosis	Drug: megadose oral methylprednisolone;Drug: IV methylprednisolone	Fred Lublin	National Multiple Sclerosis Society;Pfizer	Terminated	18 Years	50 Years	All	16	Phase 3	United States
3	NCT00112034 (ClinicalTrials.gov)	June 2003	27/5/2005	AVONEX® Combination Trial - ACT	A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.	Multiple Sclerosis, Relapsing-Remitting	Drug: Methotrexate;Drug: IV methylprednisolone	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	350	Phase 4	United States